Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Still Allows Ranbaxy Drugs To Be Imported Under Cloud

This article was originally published in PharmAsia News

Executive Summary

Even as the U.S. FDA gathers evidence against India's Ranbaxy Laboratories for allegedly adulterated drugs, the drug maker's products continue to flow into the United States. Already this year, Ranbaxy won marketing rights from the FDA for 11 more drugs. Critics of the FDA and the U.S. Customs Service complain the government is doing little to stop Ranbaxy products from entering the United States, a normal response when an importer is accused of bringing in adulterated and misbranded drugs. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts